Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Koskinas KC, Gencer B, Nanchen D, Branca M, Carballo D, Klingenberg R, Blum MR, Carballo S, Muller O, Matter CM, Lüscher TF, Rodondi N, Heg D, Wilhelm M, Räber L, Mach F, Windecker S. Koskinas KC, et al. Among authors: muller o. Eur J Prev Cardiol. 2021 Mar 23;28(1):59-65. doi: 10.1177/2047487320940102. Epub 2020 Jul 20. Eur J Prev Cardiol. 2021. PMID: 33755142
Clinical outcomes after PCI for acute coronary syndrome in unprotected left main coronary artery disease: insights from the Swiss Acute Left Main Coronary Vessel Percutaneous Management (SALVage) study.
Puricel S, Adorjan P, Oberhänsli M, Stauffer JC, Moschovitis A, Vogel R, Goy JJ, Müller O, Eeckhout E, Togni M, Wenaweser P, Meier B, Windecker S, Cook S. Puricel S, et al. Among authors: muller o. EuroIntervention. 2011 Oct 30;7(6):697-704. doi: 10.4244/EIJV7I6A112. EuroIntervention. 2011. PMID: 21986328 Free article.
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial.
Pilgrim T, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Heg D, Jüni P, Windecker S. Pilgrim T, et al. Among authors: muller o. Am Heart J. 2014 Sep;168(3):256-61. doi: 10.1016/j.ahj.2014.06.004. Epub 2014 Jun 6. Am Heart J. 2014. PMID: 25173535 Free article. Clinical Trial.
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Pilgrim T, et al. Among authors: muller o. Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1. Lancet. 2014. PMID: 25189359 Clinical Trial.
Low statin use in adults hospitalized with acute coronary syndrome.
Selby K, Nanchen D, Auer R, Gencer B, Räber L, Klingenberg R, Blum M, Marques-Vidal P, Cornuz J, Muller O, Vogt P, Jüni P, Matter CM, Windecker S, Lüscher TF, Mach F, Rodondi N. Selby K, et al. Among authors: muller o. Prev Med. 2015 Aug;77:131-6. doi: 10.1016/j.ypmed.2015.05.012. Epub 2015 May 22. Prev Med. 2015. PMID: 26007299
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Franzone A, Pilgrim T, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Räber L, Stortecky S, Wenaweser P, Jüni P, Windecker S. Franzone A, et al. Among authors: muller o. Circ Cardiovasc Interv. 2015 Jun;8(6):e002319. doi: 10.1161/CIRCINTERVENTIONS.114.002319. Circ Cardiovasc Interv. 2015. PMID: 26043895 Clinical Trial.
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blöchlinger S, Wenaweser P, Jüni P, Windecker S. Pilgrim T, et al. Among authors: muller o. EuroIntervention. 2016 Dec 10;12(11):e1343-e1354. doi: 10.4244/EIJY15M12_09. EuroIntervention. 2016. PMID: 26690319 Free article. Clinical Trial.
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Franzone A, Eberli F, Jüni P, Windecker S, Pilgrim T. Zbinden R, et al. Among authors: muller o. J Am Heart Assoc. 2016 Mar 15;5(3):e003255. doi: 10.1161/JAHA.116.003255. J Am Heart Assoc. 2016. PMID: 26979080 Free PMC article. Clinical Trial.
1,514 results